Relevance of TNF-α gene polymorphisms in nonalcoholic fatty liver disease

Expert Review of Gastroenterology and Hepatology

Volumn 5, Issue 2, 2011, Pages 155-158

  Tilg, Herbert ^a   Moschen, Alexander R ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

genetic studies; inflammation; insulin resistance; NASH; TNF

Indexed keywords

INTERLEUKIN 6; PATATIN LIKE PHOSPHOLIPASE 3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE PREDISPOSITION; DISEASE SEVERITY; DNA POLYMORPHISM; FIBROGENESIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEPATITIS; HUMAN; INSULIN RESISTANCE; LIPID METABOLISM; LIVER BIOPSY; NONALCOHOLIC FATTY LIVER; PREVALENCE; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 79954497712     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/egh.11.17     Document Type: Review

References (30)

1. Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N. Engl. J. Med. 343(20), 1467-1476 (2000).
2. Aller R, de Luis DA, Izaola O et al. G308A polymorphism of TNF-a, gene is associated with insulin resistance and histological changes in non alcoholic fatty liver disease patients. Ann. Hepatol. 9(4), 439-444 (2010).
3. Tokushige K, Takakura M, Tsuchiya-Matsushita N, Taniai M, Hashimoto E, Shiratori K. Infuence of TNF gene polymorphisms in Japanese patients with NASH and simple steatosis. J. Hepatol. 46(6), 1104-1110 (2007). (Pubitemid 46669735)
4. Hu ZW, Luo HB, Xu YM et al. Tumor necrosis factor-α gene promoter polymorphisms in Chinese patients with nonalcoholic fatty liver diseases. Acta Gastroenterol. Belg. 72(2), 215-221 (2009).
5. Yan X, Xu L, Qi J et al. sTRAIL levels and TRAIL gene polymorphisms in Chinese patients with fatty liver disease. Immunogenetics 61(8), 551-556 (2009).
6. Fernandez-Real JM, Gutierrez C, Ricart W et al. The TNF-a, gene Nco I polymorphism infuences the relationship among insulin resistance, percent body fat, and increased serum leptin levels. Diabetes 46(9), 1468-1472 (1997). (Pubitemid 27369085)
7. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW Effects of a polymorphism in the human tumor necrosis factor α promoter on transcriptional activation. Proc. Natl Acad. Sci. USA 94(7), 3195-3199 (1997). (Pubitemid 27157287)
8. Akerman P, Cote P, Yang SQ et al. Antibodies to tumor necrosis factor-α inhibit liver regeneration after partial hepatectomy. Am. J. Physiol. 263(4 Pt 1), G579-G585 (1992).
9. Yamada Y, Kirillova I, Peschon JJ, Fausto N. Initiation of liver growth by tumor necrosis factor: defcient liver regeneration in mice lacking type I tumor necrosis factor receptor. Proc. Natl Acad. Sci. USA 94(4), 1441-1446 (1997). (Pubitemid 27087870)
10. Cressman DE, Greenbaum LE, DeAngelis RA et al. Liver failure and defective hepatocyte regeneration in interleukin-6-defcient mice. Science 274(5291), 1379-1383 (1996). (Pubitemid 26391463)
11. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science 259(5091), 87-91 (1993). (Pubitemid 23036092)
12. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-α function. Nature 389(6651), 610-614 (1997). (Pubitemid 27446179)
13. Dandona P, Weinstock R, Thusu K, Abdel-Rahman E, Aljada A, Wadden T Tumor necrosis factor-α in sera of obese patients: fall with weight loss. J. Clin. Endocrinol. Metab. 83(8), 2907-2910 (1998). (Pubitemid 28493796)
14. Paz K, Hemi R, LeRoith D et al. A molecular basis for insulin resistance. Elevated serine/threonine phosphorylation of IRS-1 and IRS-2 inhibits their binding to the juxtamembrane region of the insulin receptor and impairs their ability to undergo insulin-induced tyrosine phosphorylation. J. Biol. Chem. 272(47), 29911-29918 (1997).
15. Barbuio R, Milanski M, Bertolo MB, Saad MJ, Velloso LA. Infiximab reverses steatosis and improves insulin signal transduction in liver of rats fed a high-fat diet. J. Endocrinol. 194(3), 539-550 (2007). (Pubitemid 47471222)
16. Crespo J, Cayon A, Fernandez-Gil P et al. Gene expression of tumor necrosis factor α and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 34(6), 1158-1163 (2001). (Pubitemid 33096588)
17. Haukeland JW, Damas JK, Konopski Z et al. Systemic infammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J. Hepatol. 44(6), 1167-1174 (2006).
18. Abiru S, Migita K, Maeda Y et al. Serum cytokine and soluble cytokine receptor levels in patients with non-alcoholic steatohepatitis. Liver Int. 26(1), 39-45 (2006).
19. Manco M, Marcellini M, Giannone G, Nobili V. Correlation of serum TNF-α levels and histologic liver injury scores in pediatric nonalcoholic fatty liver disease. Am. J. Clin. Pathol. 127(6), 954-960 (2007).
20. Wong VW, Hui AY, Tsang SW et al. Metabolic and adipokine profle of Chinese patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 4(9), 1154-1161 (2006). (Pubitemid 44311653)
21. Moschen AR, Molnar C, Geiger S et al. Anti-infammatory effects of excessive weight loss: potent suppression of adipose interleukin-6 and tumour necrosis factor-α expression. Gut 59, 1259-1264 (2010).
22. Li Z, Yang S, Lin H et al. Probiotics and antibodies to TNF inhibit infammatory activity and improve nonalcoholic fatty liver disease. Hepatology 37(2), 343-350 (2003). (Pubitemid 36152533)
23. Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM. Metformin reverses fatty liver disease in obese, leptin-defcient mice. Nat Med. 6(9), 998-1003 (2000).
24. Solomon SS, Mishra SK, Cwik C, Rajanna B, Postlethwaite AE. Pioglitazone and metformin reverse insulin resistance induced by tumor necrosis factor-α in liver cells. Horm. Metab. Res. 29(8), 379-382 (1997). (Pubitemid 27362061)
25. Tilg H, Moschen AR. Insulin resistance, infammation, and non-alcoholic fatty liver disease. Trends Endocrinol. Metab 19(10), 371-379 (2008).
26. Valenti L, Fracanzani AL, Dongiovanni P et al. Tumor necrosis factor α promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology 122(2), 274-280 (2002). (Pubitemid 34116980)
27. Schwimmer JB, Celedon MA, Lavine JE et al. Heritability of nonalcoholic fatty liver disease. Gastroenterology 136(5), 1585-1592 (2009).
28. Romeo S, Kozlitina J, Xing C et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 40(12), 1461-1465 (2008).
29. Tilg H, Moschen AR. Evolution of infammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 52(5), 1836-1846 (2010).
30. Dupuis J, Langenberg C, Prokopenko I et al. New genetic loci implicated in fasting glucose homeostasis and their impact on Type 2 diabetes risk. Nat Genet 42(2), 105-116 (2010).